NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 12 September 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for items 5.1 to 6.3.2
4. Michael Chambers Present for all items
5. Dawn Cooper Present for all items
6. Dr Mark Corbett Present for all items
7. Dr Prithwiraj Das Present for all items
8. Dr David Foreman Present for all items
9. John Hampson Present for all items
10. Dr Nigel Langford Present for all items
11. Dr Steven Lloyd Present for all items
12. Ugochi Nwulu Present for all items
13. Stella O’Brien Present for all items
14. Dr Clare Offer Present for all items
15. Dr Kate Ren Present for items 1.1 to 5.3.2
16. Professor Andrew Renehan Present for items 1.1 to 4.3.2
17. Dr Arpit Srivastava Present for all items
18. Elizabeth Thurgar Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Present for all items

Louise Jafferally, Project Manager & Zoom host Present for all items

Vicky Kelly, Heath Technology Assessment Adviser Items 1.1 to 4.3.2

Catherine Spanswick, Heath Technology Assessment Analyst Items 1.1 to 4.3.2

Alex Filby, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Lauren Elston, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

Sally Doss, Heath Technology Assessment Adviser Items 6.1 to 6.3.2

Zain Hussain, Heath Technology Assessment Analyst Items 6.1 to 6.3.2

External assessment group representatives present

Isaac Mackenzie, Health economist, BMJ Group Items 1.1 to 4.3.2

Victoria Wakefield, Clinical evidence analyst, BMJ Group Items 1.1 to 4.3.2

Dan Gallacher, Assistant professor in medical statistics and health technology assessment, Warwick Evidence Items 5.1 to 5.3.2

Mandy Maredza, Senior Research Fellow (Health Economics), Warwick Evidence Items 5.1 to 5.3.2

Tara Homer, Senior Research Associate, Newcastle University Items 6.1 to 6.3.2

Luke Vale, Professor of Health economics, Newcastle University Items 6.1 to 6.3.2

Clinical, Patient & NHS England experts present

Dr Camille Carroll, Associate Professor and Honorary Consultant Neurologist –clinical expertnominated by AbbVie Items 1.1 to 4.1.4

Dr Uma Nath, Consultant Neurologist – clinical expert nominated by the Association of British Neurologists Items 1.1 to 4.1.4

Philip Hockey, Patient expert nominated by Parkinson’s UK Items 1.1 to 4.1.4

Kate Hockey, Attending to support Philip Hockey Items 1.1 to 4.1.4

Marc van Grieken, Patient expert nominated by Cure Parkinson’s

 Items 1.1 to 4.1.4

Professor Peter Clark, NHS England Clinical Lead for cancer drugs

 Items 5.1 to 6.2.2

Dr Andrea Kuhnl, Consultant Haematologist – clinical expert nominated by NCRI-ACP-RCP-RCR Items 5.1 to 5.1.4

Dr Cathy Burton, Consultant Haematologist – clinical expert nominated by NCRI-ACP-RCP-RCR Items 5.1 to 5.1.4

Michael Clancy, Patient expert nominated by Lymphoma Action Items 5.1 to 5.1.4

Professor Francesco Forconi, Professor of Haematology and Consultant Haematologist – clinical expert, nominated by BeiGene Items 6.1 to 6.1.4

Dr Rosalynd Johnston, Consultant Haematologist – clinical expert, nominated by the UK Chronic Lymphocytic Leukaemia Forum Items 6.1 to 6.1.4

Nick York, Patient expert, nominated by Leukaemia Care Items 6.1 to 6.2.2

Observers present

Victoria Charlton, Researcher and lecturer in policy and bioethics, King’s College London Items 1.1 to 4.3.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Richard Nicholas, welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Alex Cale, Chamkhor Dhillon, Dr Rob Forsyth, Dr Pedro Saramago Goncalves, Iain McGowan and Dr Britta Stordal.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meetings held on Tuesday 11 July 2023 and Tuesday 08 August 2023.

### Appraisal of Foslevodopa-foscarbidopa for treating Parkinson’s disease with motor symptoms [ID3876]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AbbVie.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10772/documents).
		3. The Chair led a discussion of the consultation comments presented to the committee.
		4. The committee discussed confidential information submitted for this item.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10772>

### Appraisal of Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic therapies [ID3943]

* 1. Part 1 – Open session
		1. The Chair, Professor Stephen O’Brien, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from SOBI.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10831/documents).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Kate Ren, Dr Nigel Langford and Ugochi Nwulu.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10831>

### Appraisal of Zanubrutinib for treating chronic lymphocytic leukaemia [ID5078]

* 1. Part 1 – Open session
		1. The Chair, Dr Richard Nicholas welcomed the invited experts, external assessment group representatives, members of the public and company representatives from BeiGene.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10964/documents).
		3. Dr Richard Nicholas led a discussion of the consultation comments presented to the committee.
	2. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10964>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 10 October 2023 and will start promptly at 9.00am.